Iqirvo® (elafibranor)
for Primary Biliary Cholangitis
Iqirvo (elafibranor) is used to treat primary biliary cholangitis (PBC) in adults, in combination with ursodeoxycholic acid (UDCA) for those not responding well to UDCA or alone for those who cannot tolerate UDCA. Iqirvo is a PPAR agonist that activates PPAR-alpha and PPAR-delta receptors, which regulate energy homeostasis and metabolic function. While its exact mechanism in PBC is not fully understood, it is believed to block bile acid production.
